ATTR-CM: Economic Burden & Unmet Patient Needs

The economic burden of ATTR-CM – transthyretin amyloid cardiomyopathy – extends far beyond healthcare costs, impacting patients’ livelihoods and creating significant unmet needs. While advances in treatment offer hope, access and affordability remain substantial barriers for many, and the full scope of the condition’s economic and social consequences is only beginning to be understood. Here’s particularly true as diagnosis rates remain low, delaying intervention and exacerbating both health outcomes and financial strain.

Understanding ATTR-CM and its Impact

ATTR-CM is a rare, progressive disease caused by the buildup of abnormal amyloid protein deposits in the heart. This buildup stiffens the heart muscle, leading to heart failure. There are two main types: hereditary ATTR-CM (hATTR-CM), caused by a genetic mutation, and wild-type ATTR-CM (wtATTR-CM), which develops without a known genetic cause. Both forms can lead to debilitating symptoms, including shortness of breath, fatigue, swelling in the legs and ankles, and irregular heartbeat.

The economic impact stems from several factors. Direct medical costs include hospitalizations, diagnostic tests (such as cardiac MRI and bone scintigraphy), and medications – including the newer, and often expensive, disease-modifying therapies. Indirect costs encompass lost productivity due to illness, disability, and premature mortality. For patients and their families, these financial pressures can be devastating, potentially leading to debt, reduced quality of life, and difficulty maintaining employment.

Recent Financial Updates from Intellia Therapeutics

Recent financial reports from companies like Intellia Therapeutics, while focused on gene editing technologies for various conditions, highlight the broader pharmaceutical industry’s investment in addressing amyloidosis and related cardiac conditions. The company’s third quarter 2025 results and updates, as well as their second quarter 2025 financial results , demonstrate ongoing research and development efforts in the space, which could eventually impact treatment costs and accessibility. However, these reports do not directly address the economic impact on patients with ATTR-CM.

Diagnostic Delays and the Cost of Uncertainty

A significant contributor to the economic burden is the delay in diagnosis. Symptoms of ATTR-CM can mimic other, more common heart conditions, leading to misdiagnosis or delayed referral to specialists. This diagnostic odyssey can span years, during which the disease progresses, and patients may undergo unnecessary and costly tests and treatments for other conditions. Early and accurate diagnosis is crucial not only for improving patient outcomes but also for reducing overall healthcare expenditures.

The lack of widespread awareness among healthcare professionals also contributes to the problem. Many physicians are unfamiliar with ATTR-CM, and may not consider it in their differential diagnosis, particularly in younger patients or those without a family history of the disease. This underscores the demand for increased education and training for healthcare providers.

Unmet Needs Beyond Medical Treatment

The challenges faced by individuals with ATTR-CM extend beyond medical care. Many patients experience difficulty maintaining employment due to their symptoms, leading to lost income and financial hardship. The need for caregiver support is also significant, as patients often require assistance with daily activities. Caregivers may also experience financial strain due to lost wages or the need to reduce their work hours.

access to specialized care centers and multidisciplinary teams can be limited, particularly for patients living in rural or underserved areas. This can create disparities in care and exacerbate the economic burden for those who must travel long distances to receive treatment. The emotional and psychological toll of living with a chronic, progressive disease should not be underestimated, and access to mental health support is essential.

The Role of Social Needs Screening

Recognizing the impact of social determinants of health, initiatives like the Accountable Health Communities Screening Tool are gaining traction. This standardized screening process, developed by the National Academy of Medicine, aims to identify health-related social needs – such as food insecurity, housing instability, and transportation barriers – that can impact health outcomes. Addressing these needs can improve access to care, reduce healthcare costs, and enhance the overall well-being of patients with ATTR-CM.

What Comes Next: Research, Advocacy, and Policy Changes

Addressing the economic impact and unmet needs in ATTR-CM requires a multi-faceted approach. Continued research is needed to develop more effective and affordable treatments, as well as to improve diagnostic methods and identify individuals at risk. Advocacy efforts are crucial to raise awareness of the disease, increase funding for research, and promote policies that improve access to care.

innovative payment models and financial assistance programs may be needed to help patients afford the high cost of treatment. Collaboration between healthcare providers, researchers, policymakers, and patient advocacy groups is essential to ensure that individuals with ATTR-CM receive the care and support they need to live full and productive lives. Ongoing surveillance of disease prevalence and economic burden will be critical to track progress and identify areas where further intervention is needed.